NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000015997

Registered date:20/12/2014

WT1 peptide-based cancer vaccine for long-term maintenance of anti-tumor immunity

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedsolid tumor, malignant lymphoma, acute leukemia
Date of first enrollment2014/12/24
Target sample size56
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Administration of WT1 peptide vaccine

Outcome(s)

Primary OutcomeDTH to WT1 peptide Frequency of WT1 specific CTLs
Secondary OutcomeSafety 1 Numbers and frequencies of adverse effects defined in NCI-CTCAE v4.0 2 Frequencies of hematological- and non-hematological adverse effects which result in suspension or withdrawal of WT1 peptide vaccine Anti-tumor effects Anti-tumor effects are evaluated at 3-6 months intervals by the method described elsewhere.

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum85years-old
GenderMale and Female
Include criteria
Exclude criteria1. having severe infectious disease 2. having developed adverse effects (grade >=4) in the prior WT1 peptide vaccine trial 3. having severe complications 4. having severe mental disorders

Related Information

Contact

public contact
Name Yusuke Oji
Address 1-7 Yamada-oka Suita city Osaka, Japan Japan
Telephone 06-6879-2597
E-mail oji@sahs.med.osaka-u.ac.jp
Affiliation Osaka University Graduate School of Medicine Cancer Stem Cell Biology
scientific contact
Name Haruo Sugiyama
Address 1-7 Yamada-oka Suita city Osaka, Japan Japan
Telephone 06-6879-2597
E-mail sugiyama@sahs.med.osaka-u.ac.jp
Affiliation Osaka University Graduate School of Medicine Dept Functional Diagnostic Science